PrecisionLife Mechanostics - mechanism-based precision medicine

The most accurate way to predict disease risk

The complex biology underpinning chronic diseases has made them difficult to diagnose and treat effectively, leaving millions of patients with unmet needs and making healthcare unaffordable.

Mechanostics are biomarker-driven precision medicine tests for chronic diseases that accurately identify disease risk, underlying causes, and the most effective treatments for individual patients. All consistent with a patient’s specific risk factors and mechanisms.

Mechanostics enable:
Determination of the mechanistic cause of a person's disease
Lifetime prediction and earliest detection of disease
Rapid and accurate differential triage
Personalized treatment strategies and therapy optimization

Mechanism-Based Precision Medicine

Enabling accurate risk scoring, differential triage, treatment optimization & more

Disease Risk Prediction

Patient Triage

Treatment Optimization

Clinical Trial Recruitment

Early Intervention & Prevention

Disease Risk Prediction

Identifying at-risk patients before symptoms emerge

Mechanostics enable proactive healthcare by detecting subtle, highly predictive genotypic signatures long before clinical symptoms arise. Using combinatorial analytics, our tests identify individuals at elevated risk based on the specific biological mechanisms that drive disease.

These non-invasive tests use low-cost buccal swabs to collect DNA from the lining of the patient's cheek, and are compatible with widely available genotyping arrays - making large-scale population screening practical and cost-effective.

For diagnostics

Diagnostics providers can offer next-generation risk prediction tools that add clinical value and create new revenue streams through longitudinal patient engagement.

For healthcare

Healthcare providers benefit from earlier interventions, reduced late-stage diagnoses, and the ability to shift from reactive treatment to preventative care – improving outcomes while lowering long-term costs.

Differential Triage & Accelerated Diagnosis

Pinpointing disease mechanisms for faster, more accurate referrals

Many chronic conditions have overlapping symptoms that can often result in delayed referrals and incorrect diagnoses.

Mechanostics identify the underlying biological drivers of disease in each patient, provide clear, actionable insights to accurately distinguishing between conditions.

This enables differential triage across chronic diseases to effectively manage non-specific referrals, so that patients can be allocated to the right specialty for the right procedures – preventing backlogs, reducing the need for specialist referrals and expensive confirmatory testing, and avoiding ineffective treatments.

For diagnostics

Diagnostics providers gain high-value tools that enhance clinical accuracy, integrate seamlessly with existing genotyping platforms, and improve operational efficiency.

For healthcare

Healthcare systems benefit from reduced diagnostic delays, fewer unnecessary investigations, and faster triage to the right care pathways - optimizing resource allocation to relieve pressure on specialist services and improve patient outcomes.

Treatment Optimization

Targeting treatments to the biology that matters

Mechanostics enable targeted therapeutic decision-making by identifying the specific disease mechanisms active in each patient – stratifying patients by mechanism, and showing their most likely effective therapy.

These insights determine which patients are most likely to benefit from a given treatment – or avoid adverse reactions.

This approach enables clinicians to prioritize the treatments that align with the patient’s underlying disease biology. For example, mechanostics tests can identify chronic kidney disease patients who are most likely to benefit from Kerendia and predict complications in type-II diabetes patients to inform early therapeutic intervention and accelerate patient benefit.

For biopharma & diagnostics

Biopharmaceutical and diagnostics companies can deploy our mechanostic tests as high-value companion diagnostics that support personalized treatment strategies and improve therapy ROI.

For healthcare

Healthcare providers benefit from reduced trial-and-error prescribing, lower drug costs, and better therapeutic outcomes.

Clinical Trial Recruitment

Smarter recruitment for faster, more effective trials

Mechanostics transform trial recruitment by identifying patients with the specific genotypic and mechanistic profiles targeted by investigational therapies - improving signal detection and trial efficiency from the outset.

Our low-cost, non-invasive tests use saliva or buccal swabs and run on standard genotyping arrays compatible with CLIA/CAP-accredited labs worldwide. This makes mechanostic screening highly scalable, enabling rapid pre-screening of large patient populations across diverse sites and geographies.

For clinical trial design & enrichment

Biotech and pharma partners can run smaller, faster, and more successful trials by enrolling patients most likely to respond. Mechanistics reduce heterogeneity, improve inclusion criteria, and support enriched trial design strategies.

By combining precision recruitment with global scalability, mechanostics lower drug development risk, accelerate timelines, and increase the probability of success – helping to bring precision therapies to market faster.

Early Intervention & Prevention

Delaying and preventing disease with clinically actionable insights

Mechanostics detect an individual's lifetime risk of developing specific chronic diseases by identifying the genotypic signatures and biological mechanisms that drive disease onset.

This empowers clinicians to implement tailored early interventions - from lifestyle modifications and active monitoring to prophylactic therapies - to delay or even prevent disease progression.

PrecisionLife is uniquely positioned to go further, identifying actively protective biology that informs the development of next-generation prophylactic drugs and mRNA vaccines targeting major chronic conditions.

For diagnostics

Diagnostics providers can expand the value of routine testing by offering predictive tools that support prevention-focused care models and public health strategies.

For healthcare

Healthcare systems benefit from a measurable reduction in future disease burden, enabling more sustainable care delivery and longer, healthier lives for patients.

Mechanostics benefits for providers:

1. Personalized Treatment Guidance
Mechanostics identify disease mechanisms, helping tailor interventions to individual patient needs.

2. Clearer Clinical Decision-Making
Accelerates triage and diagnosis of overlapping symptom conditions, reducing time to treatment.

3. Practical in Routine Care
Delivered via non-invasive samples, usable in primary care or at home without specialist infrastructure.

4. Earlier, Better Outcomes
Enables proactive care by identifying risks before severe symptoms develop - saving clinician time and improving patient quality of life.

Mechanostics allow payors to:

1. Reduce Costs of Care
Early risk prediction and stratification lowers unnecessary treatments and hospitalizations, reducing spend.

2. Promote Health Equity
Common variant combinations improve predictive accuracy across diverse ancestries and populations.

3. Streamline Diagnosis
Low-cost, non-invasive testing supports efficient triage and reduces burden on healthcare systems.

4. Enable Reimbursement
Demonstrated precision in stratification supports long-term cost savings and payer adoption.

Mechanostics offer diagnostics providers:

1. Access to Major Unaddressed Markets
Mechanostics target underserved chronic conditions responsible for over 80% of healthcare costs - unlocking large new diagnostic markets.

2. Scalable Revenue Growth
High-prevalence conditions support recurring revenues via self-pay and licensing models across a global patient base.

3. Easy Lab Deployment
Tests use standard genotyping platforms already in CLIA labs worldwide - enabling rapid, low-cost global rollout.

4. Competitive Differentiation
Outperform polygenic/metabolomic tests with disease-specific triage and mechanistic insight - creating real product advantage.

Mechanostics benefits for patients:

1. Faster, More Accurate Diagnosis
Mechanostics uncover the root cause of symptoms, reducing diagnostic delays and misdiagnoses in complex chronic conditions.

2. Personalized, Effective Treatments
By revealing each patient’s specific disease mechanisms, tests support therapies that are more likely to work and less likely to cause harm.

3. Convenient and Non-Invasive
Tests are simple, saliva-based, and can be taken at home or in a primary care setting – no hospital visits or invasive procedures required.

4. Empowered, Preventive Care
Mechanostics identify risk before disease develops, enabling patients to take proactive steps and work with their care teams to stay healthier, longer.

Tab heading

Mechanostics benefits for providers:

1. Personalized Treatment Guidance
Mechanostics identify disease mechanisms, helping tailor interventions to individual patient needs.

2. Clearer Clinical Decision-Making
Accelerates triage and diagnosis of overlapping symptom conditions, reducing time to treatment.

3. Practical in Routine Care
Delivered via non-invasive samples, usable in primary care or at home without specialist infrastructure.

4. Earlier, Better Outcomes
Enables proactive care by identifying risks before severe symptoms develop - saving clinician time and improving patient quality of life.

Mechanostics allow payors to:

1. Reduce Costs of Care
Early risk prediction and stratification lowers unnecessary treatments and hospitalizations, reducing spend.

2. Promote Health Equity
Common variant combinations improve predictive accuracy across diverse ancestries and populations.

3. Streamline Diagnosis
Low-cost, non-invasive testing supports efficient triage and reduces burden on healthcare systems.

4. Enable Reimbursement
Demonstrated precision in stratification supports long-term cost savings and payer adoption.

Mechanostics offer diagnostics providers:

1. Access to Major Unaddressed Markets
Mechanostics target underserved chronic conditions responsible for over 80% of healthcare costs - unlocking large new diagnostic markets.

2. Scalable Revenue Growth
High-prevalence conditions support recurring revenues via self-pay and licensing models across a global patient base.

3. Easy Lab Deployment
Tests use standard genotyping platforms already in CLIA labs worldwide - enabling rapid, low-cost global rollout.

4. Competitive Differentiation
Outperform polygenic/metabolomic tests with disease-specific triage and mechanistic insight - creating real product advantage.

How mechanostics compare with traditional diagnostics

	Mechanostics	Diagnostics
Test	Genotype	Metabolomic/genetic
Sample type	Buccal swab (non-invasive)	Various (non-invasive – surgery)
Cost per test	$	$ – $$$
Administration	Self-test / Point of care	Point of care / Surgical
Readout	Disease risk and protective effects. Mechanisms underpinning disease.	Active disease status. [Surrogate] of disease progression.
Patient insights	Most likely effective treatment. Expected symptoms / clinical presentation. Likely disease trajectory (pre-symptomatic).	[Surrogate] marker, may be linked to clinical endpoint. [Stage of disease, progression rate].
Applications	Differential triage between similar conditions. Therapy selection by disease + mechanism. Clinical trial design & recruitment biomarkers. Early (pre-symptomatic) detection of disease risk for personal preventative health.	Confirmation of disease after presentation of clinical symptoms. Early pre-symptom screening. Measurement of residual disease. [Therapy selection by disease].

From sample to solution

A simple test

Non-invasive sample taken at home or in a primary care setting, tested against an Axiom genotyping array

Rapid results

Results delivered by our clinical decision support platform, translating disease mechanisms into actionable insights

Predicting risk

Pre-symptomatic risk detection allowing for proactive monitoring, lifestyle changes, or therapeutic interventions

Detecting cause

Identifying the underlying biology driving disease, enabling personalized care based on each patient’s specific mechanisms

Mechanostics®

Mechanism-based precision medicine tests for chronic diseases

First-in-class genotyping tests that accurately predict disease risk, mechanistic cause, and most effective treatments for patients

The most accurate way to predict disease risk

Low-cost, scalable, rapid & non-invasive

Predict and prevent chronic diseases that account for over 80% of all healthcare costs

Mechanism-Based Precision Medicine

Disease Risk Prediction

Identifying at-risk patients before symptoms emerge

For diagnostics

For healthcare

Differential Triage & Accelerated Diagnosis

Pinpointing disease mechanisms for faster, more accurate referrals

For diagnostics

For healthcare

Treatment Optimization

Targeting treatments to the biology that matters

For biopharma & diagnostics

For healthcare

Clinical Trial Recruitment

Smarter recruitment for faster, more effective trials

For clinical trial design & enrichment

Early Intervention & Prevention

Delaying and preventing disease with clinically actionable insights

For diagnostics

For healthcare

Major benefits for patients, payors & providers

Mechanostics benefits for providers:

Mechanostics allow payors to:

Mechanostics offer diagnostics providers:

Mechanostics benefits for patients:

Tab heading

Mechanostics benefits for providers:

Mechanostics allow payors to:

Mechanostics offer diagnostics providers:

How mechanostics compare with traditional diagnostics

From sample to solution

A simple test

Rapid results

Predicting risk

Detecting cause

"This unrivaled understanding of the mechanistic causes of disease enables us to better determine disease risk in our patients and specify which therapies are most likely to be effective in treating them."

Patients are counting on us